T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
T2 Biosystems (NASDAQ:TTOO), a leader in rapid sepsis detection, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management will host one-on-one meetings on September 11, 2024. Investors can access a virtual presentation on-demand through T2 Biosystems' website starting September 9, 2024, at 7:00 am ET.
This conference participation highlights T2 Biosystems' commitment to engaging with investors and showcasing its innovative technology in sepsis detection. The company's presence at this global investment event could potentially impact its stock performance and investor relations.
T2 Biosystems (NASDAQ:TTOO), un leader nella rilevazione rapida della sepsi, ha annunciato la sua partecipazione al 26° Congresso Annuale di Investimenti Globali H.C. Wainwright. La direzione dell'azienda ospiterà incontri one-to-one il 11 settembre 2024. Gli investitori possono accedere a una presentazione virtuale on-demand tramite il sito web di T2 Biosystems a partire dal 9 settembre 2024, alle 7:00 ET.
Questa partecipazione alla conferenza evidenzia l'impegno di T2 Biosystems nel coinvolgere gli investitori e nel mostrare la sua tecnologia innovativa nella rilevazione della sepsi. La presenza dell'azienda in questo evento di investimento globale potrebbe avere un impatto sulle performance azionarie e sulle relazioni con gli investitori.
T2 Biosystems (NASDAQ:TTOO), un líder en la detección rápida de sepsis, anunció su participación en la 26ª Conferencia Anual de Inversiones Globales H.C. Wainwright. La dirección de la empresa llevará a cabo reuniones uno a uno el 11 de septiembre de 2024. Los inversores podrán acceder a una presentación virtual bajo demanda a través del sitio web de T2 Biosystems a partir del 9 de septiembre de 2024, a las 7:00 a.m. ET.
Esta participación en la conferencia destaca el compromiso de T2 Biosystems con el involucramiento de inversores y la exhibición de su tecnología innovadora en la detección de sepsis. La presencia de la empresa en este evento de inversión global podría influir en su rendimiento accionario y en las relaciones con los inversores.
T2 바이오시스템즈 (NASDAQ:TTOO), 신속한 패혈증 탐지의 선두주자가 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 2024년 9월 11일에 일대일 미팅을 주최할 예정입니다. 투자자들은 2024년 9월 9일 오전 7시 ET부터 T2 바이오시스템즈 웹사이트를 통해 온디맨드 가상 발표에 접근할 수 있습니다.
이번 컨퍼런스 참가로 T2 바이오시스템즈가 투자자와의 소통과 패혈증 탐지의 혁신적인 기술을 선보이겠다는 의지를 강조합니다. 이 글로벌 투자 행사에서의 회사의 존재는 주가 성과와 투자자 관계에 영향을 미칠 수 있습니다.
T2 Biosystems (NASDAQ:TTOO), un leader dans la détection rapide de la sepsie, a annoncé sa participation à la 26ème Conférence Annuelle d'Investissement Mondial H.C. Wainwright. La direction de l'entreprise organisera des réunions individuelles le 11 septembre 2024. Les investisseurs pourront accéder à une présentation virtuelle à la demande sur le site web de T2 Biosystems à partir du 9 septembre 2024, à 7h00 ET.
Cette participation à la conférence met en avant l'engagement de T2 Biosystems à interagir avec les investisseurs et à mettre en valeur sa technologie innovante en matière de détection de sepsie. La présence de l'entreprise lors de cet événement d'investissement mondial pourrait avoir un impact sur sa performance boursière et sur ses relations avec les investisseurs.
T2 Biosystems (NASDAQ:TTOO), ein führendes Unternehmen in der schnellen Sepsiserkennung, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. Das Management des Unternehmens wird am 11. September 2024 persönliche Meetings anbieten. Investoren können ab dem 9. September 2024, um 7:00 Uhr ET eine virtuelle Präsentation auf der Website von T2 Biosystems auf Abruf abrufen.
Die Teilnahme an dieser Konferenz hebt das Engagement von T2 Biosystems hervor, mit Investoren in Kontakt zu treten und seine innovative Technologie zur Sepsiserkennung zu präsentieren. Die Präsenz des Unternehmens auf diesem globalen Investment-Event könnte potenziell Einfluss auf die Aktienkursentwicklung und die Beziehungen zu den Investoren haben.
- None.
- None.
LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference.
Management will host 1x1 meetings on Wednesday, September 11, 2024. Interested parties may access management’s corresponding virtual presentation on-demand on the “Investors” section of the Company’s website at www.t2biosystems.com beginning at 7:00 am ET on Monday, September 9, 2024.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
When is T2 Biosystems (TTOO) participating in the H.C. Wainwright Global Investment Conference?
How can investors access T2 Biosystems' (TTOO) presentation for the H.C. Wainwright conference?
What is T2 Biosystems' (TTOO) main focus in the medical field?
Where is T2 Biosystems (TTOO) headquartered?
